MeSH term
Frequency | Condition_Probility | Adult | 70 | 0.0 |
Humans | 284 | 0.0 |
Male | 93 | 0.0 |
Middle Aged | 77 | 0.0 |
Reference Values | 8 | 0.0 |
Risk Factors | 2 | 0.0 |
Animals | 43 | 0.0 |
Cell Line | 23 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Rabbits | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 189 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 53 | 0.0 |
Transcription, Genetic | 7 | 0.0 |
Aged | 67 | 0.0 |
Blotting, Western | 26 | 0.0 |
Bronchi/*metabolism | 2 | 6.0 |
Cells, Cultured | 24 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 15 | 0.0 |
Epidermal Growth Factor/*pharmacology | 2 | 0.0 |
Female | 105 | 0.0 |
Mucins/*metabolism | 32 | 32.0 |
RNA, Messenger/metabolism | 26 | 0.0 |
Respiratory Mucosa/metabolism | 4 | 26.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 3 | 0.0 |
English Abstract | 9 | 0.0 |
Aged, 80 and over | 30 | 0.0 |
CA-15-3 Antigen/biosynthesis | 2 | 18.0 |
Immunohistochemistry | 71 | 0.0 |
Mucins/*biosynthesis | 15 | 39.0 |
Paget's Disease, Extramammary/*metabolism/pathology | 3 | 60.0 |
Penis/metabolism/pathology | 2 | 100.0 |
Scrotum/metabolism/pathology | 2 | 100.0 |
Tumor Markers, Biological/*biosynthesis | 2 | 2.0 |
Vulva/metabolism/pathology | 2 | 100.0 |
CA-15-3 Antigen/metabolism | 7 | 21.0 |
Helicobacter Infections/*metabolism | 2 | 16.0 |
*Helicobacter pylori | 4 | 3.0 |
Immunoenzyme Techniques | 20 | 0.0 |
Lewis Blood-Group System/*metabolism | 3 | 37.0 |
Base Sequence | 27 | 0.0 |
Carcinoma, Squamous Cell | 2 | 1.0 |
DNA Primers | 13 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Lung Neoplasms | 4 | 3.0 |
Mucins/biosynthesis/*genetics | 4 | 23.0 |
Polymerase Chain Reaction | 11 | 0.0 |
Receptor, Epidermal Growth Factor/*physiology | 3 | 2.0 |
Transcription Factor, Sp1/*metabolism | 2 | 0.0 |
Tumor Cells, Cultured | 25 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Mucins/genetics/metabolism | 3 | 37.0 |
Time Factors | 10 | 0.0 |
Cell Differentiation | 14 | 0.0 |
Cell Transplantation | 2 | 2.0 |
Coculture Techniques | 3 | 0.0 |
Epithelial Cells/*cytology | 2 | 8.0 |
Mice | 23 | 0.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Mice, Nude | 4 | 0.0 |
Stem Cells/*cytology | 3 | 3.0 |
Gastric Mucosa/metabolism/pathology | 2 | 9.0 |
Hyperplasia | 6 | 1.0 |
Intestinal Mucosa/pathology | 3 | 5.0 |
Mucins/metabolism | 11 | 22.0 |
Mucins/*secretion | 3 | 60.0 |
Pancreatic Neoplasms/*metabolism | 2 | 2.0 |
Protein Kinase C/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 13 | 0.0 |
Signal Transduction/drug effects | 3 | 0.0 |
Up-Regulation/drug effects | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 3 | 1.0 |
Neoplasm Proteins/genetics | 5 | 1.0 |
CA-15-3 Antigen/analysis | 3 | 4.0 |
Lymphatic Metastasis | 5 | 0.0 |
Mucins/*analysis | 10 | 26.0 |
Gene Expression Regulation | 9 | 0.0 |
Mucus/secretion | 2 | 25.0 |
Rats | 10 | 0.0 |
Conjunctiva/*metabolism | 2 | 14.0 |
Epithelial Cells/metabolism | 6 | 1.0 |
Goblet Cells/*metabolism | 3 | 50.0 |
Mucins/*physiology | 2 | 15.0 |
Centrifugation, Density Gradient | 10 | 2.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Epithelial Cells | 4 | 0.0 |
Glycosylation | 17 | 1.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Tissue Distribution | 4 | 0.0 |
CA-15-3 Antigen/*metabolism | 2 | 3.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Tumor Markers, Biological/*metabolism | 8 | 1.0 |
Severity of Illness Index | 3 | 0.0 |
HT29 Cells | 5 | 2.0 |
Antibody Specificity | 4 | 0.0 |
Comparative Study | 37 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
Mucins/genetics/immunology/*metabolism | 3 | 60.0 |
Peptide Fragments/immunology | 3 | 1.0 |
RNA/isolation & purification | 2 | 3.0 |
Reverse Transcriptase Polymerase Chain Reaction | 43 | 0.0 |
Tears/*metabolism | 2 | 13.0 |
Signal Transduction | 3 | 0.0 |
Gastroscopy | 2 | 4.0 |
Metaplasia/metabolism/pathology | 2 | 25.0 |
Mucins/classification/*metabolism | 4 | 100.0 |
Neoplasm Staging | 9 | 0.0 |
Retrospective Studies | 6 | 0.0 |
Stomach Neoplasms/classification/*metabolism/pathology | 2 | 66.0 |
Tumor Markers, Biological | 5 | 1.0 |
Chronic Disease | 7 | 0.0 |
*Gene Expression | 10 | 0.0 |
Mucins/analysis/*genetics | 8 | 53.0 |
Probability | 3 | 0.0 |
Prospective Studies | 5 | 0.0 |
RNA, Messenger/analysis | 17 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Neoplasm Proteins/metabolism | 6 | 1.0 |
Disease Progression | 4 | 0.0 |
Gastric Mucosa/metabolism/*pathology | 2 | 20.0 |
Gene Expression | 25 | 0.0 |
Homeodomain Proteins/*genetics/metabolism | 2 | 2.0 |
Intestinal Mucosa/metabolism/*pathology | 2 | 18.0 |
Metaplasia | 13 | 14.0 |
Case-Control Studies | 9 | 0.0 |
Cystic Fibrosis/*metabolism | 3 | 6.0 |
Immunohistochemistry/methods | 6 | 0.0 |
Lung/*chemistry | 2 | 15.0 |
Trachea/chemistry | 2 | 28.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
Mucins/*immunology | 2 | 9.0 |
Leukocyte Count | 2 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 12 | 0.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
Mucus/*metabolism | 2 | 28.0 |
Adenocarcinoma/*metabolism | 2 | 2.0 |
Carbohydrates/chemistry | 2 | 20.0 |
Glycoproteins/chemistry/isolation & purification | 2 | 40.0 |
RNA, Messenger/biosynthesis | 6 | 0.0 |
Adenocarcinoma/*genetics | 3 | 2.0 |
*Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Tumor Markers, Biological/*analysis | 6 | 0.0 |
CA-15-3 Antigen/*analysis | 3 | 17.0 |
Prognosis | 15 | 0.0 |
Protein p53/analysis | 3 | 1.0 |
Amino Acid Sequence | 24 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Biological Markers/analysis | 5 | 0.0 |
Diagnosis, Differential | 4 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Intermediate Filament Proteins/analysis | 2 | 5.0 |
Intestines/*pathology | 2 | 15.0 |
Keratin/*analysis | 2 | 6.0 |
Mucins/analysis | 5 | 13.0 |
Stomach/*pathology | 2 | 28.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
CA-15-3 Antigen/*biosynthesis | 2 | 8.0 |
Fluorescent Antibody Technique, Indirect | 5 | 0.0 |
MAP Kinase Signaling System/drug effects | 2 | 2.0 |
Naphthalenes/pharmacology | 2 | 2.0 |
*Signal Transduction | 2 | 0.0 |
Up-Regulation | 9 | 0.0 |
Colorectal Neoplasms/*genetics | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
In Situ Hybridization | 33 | 1.0 |
Intestinal Mucosa/metabolism | 4 | 3.0 |
CA-15-3 Antigen/*analysis/genetics | 2 | 22.0 |
Mucins/*analysis/genetics | 2 | 25.0 |
Centrifugation | 2 | 2.0 |
Cesium/pharmacology | 2 | 18.0 |
Chlorides/pharmacology | 2 | 5.0 |
Chromatography, Gel | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 8 | 0.0 |
Protein Binding | 5 | 0.0 |
Trachea/metabolism | 3 | 16.0 |
Protein Isoforms/genetics | 2 | 0.0 |
Lung Neoplasms/*genetics | 2 | 0.0 |
Mucins/*genetics | 43 | 39.0 |
Respiratory Mucosa/*metabolism | 3 | 21.0 |
Adolescent | 9 | 0.0 |
Alleles | 2 | 0.0 |
Cloning, Molecular | 13 | 0.0 |
Cysteine | 2 | 1.0 |
Gene Library | 2 | 0.0 |
Molecular Sequence Data | 35 | 0.0 |
Mucins/*chemistry/*genetics | 2 | 100.0 |
Restriction Mapping | 4 | 0.0 |
Sequence Alignment | 7 | 0.0 |
Membrane Glycoproteins/*metabolism | 2 | 0.0 |
Anti-Bacterial Agents/*pharmacology | 2 | 1.0 |
Epithelial Cells/drug effects/metabolism | 3 | 3.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 4 | 0.0 |
Phosphorylation | 4 | 0.0 |
Carbohydrate Sequence | 5 | 1.0 |
Mucins/genetics/*metabolism | 14 | 36.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
Child | 10 | 0.0 |
Mucins/analysis/*biosynthesis | 2 | 50.0 |
Chromosome Mapping | 4 | 0.0 |
Gastric Mucosa/pathology | 3 | 7.0 |
Tandem Repeat Sequences | 4 | 2.0 |
Growth Substances/*metabolism | 4 | 2.0 |
Microscopy, Confocal | 5 | 0.0 |
*Muscle Proteins | 12 | 4.0 |
*Neuropeptides | 12 | 9.0 |
Peptides/*metabolism | 6 | 3.0 |
Phenotype | 11 | 0.0 |
Blotting, Northern | 10 | 0.0 |
CA-15-3 Antigen/genetics/metabolism | 3 | 50.0 |
Follow-Up Studies | 4 | 0.0 |
Stomach Neoplasms/*metabolism/mortality/pathology | 3 | 23.0 |
Survival Rate | 6 | 0.0 |
Culture Media | 4 | 0.0 |
Gene Expression Regulation/*drug effects | 6 | 0.0 |
Goblet Cells/drug effects/*metabolism | 2 | 66.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Intestinal Mucosa/*metabolism | 2 | 2.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Transfection | 4 | 0.0 |
Cell Division | 4 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
Mucins/*genetics/metabolism | 9 | 32.0 |
RNA, Messenger/genetics | 8 | 0.0 |
Gastric Mucin/*metabolism | 5 | 62.0 |
Gestational Age | 4 | 0.0 |
Histocytochemistry | 2 | 0.0 |
Keratin/analysis | 3 | 1.0 |
Gene Expression Regulation/drug effects/*physiology | 4 | 5.0 |
Receptors, Retinoic Acid/metabolism | 2 | 2.0 |
Tretinoin/pharmacology | 2 | 0.0 |
Biopsy | 4 | 0.0 |
Bronchoscopy | 2 | 3.0 |
Image Processing, Computer-Assisted | 3 | 0.0 |
Mucins/genetics | 5 | 26.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Cell Culture Techniques | 3 | 0.0 |
Keratin/metabolism | 4 | 2.0 |
Bronchi/cytology/*metabolism | 2 | 14.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Adenocarcinoma/*metabolism/pathology | 2 | 1.0 |
Mucins/*biosynthesis/genetics | 6 | 27.0 |
Respiratory Mucosa/cytology/*metabolism | 2 | 20.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Multivariate Analysis | 4 | 0.0 |
Gallbladder/*metabolism | 3 | 23.0 |
Organ Specificity | 4 | 0.0 |
Stomach Neoplasms/*metabolism | 4 | 8.0 |
Cervix Neoplasms/*chemistry/pathology | 2 | 25.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Barrett Esophagus/genetics/*metabolism | 2 | 100.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Epithelial Cells/cytology/physiology | 3 | 9.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Luciferases/metabolism | 3 | 0.0 |
Models, Biological | 3 | 0.0 |
Mutation | 2 | 0.0 |
Transcription Factor AP-1/*metabolism | 2 | 1.0 |
Cell Count | 2 | 0.0 |
Keratin/*metabolism | 3 | 9.0 |
Tumor Markers, Biological/metabolism | 6 | 1.0 |
Metaplasia/metabolism | 2 | 15.0 |
Carcinogens/*pharmacology | 2 | 3.0 |
Cell Adhesion/drug effects | 2 | 0.0 |
Neoplasm Invasiveness | 6 | 0.0 |
RNA, Neoplasm/biosynthesis/genetics | 2 | 3.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 3 | 0.0 |
Mucins/*genetics/*metabolism | 2 | 25.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Acute Disease | 2 | 0.0 |
Adenocarcinoma, Mucinous/metabolism/pathology | 2 | 66.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Epithelial Cells/metabolism/microbiology | 2 | 22.0 |
Stomach Neoplasms | 2 | 6.0 |
Colorectal Neoplasms/metabolism/*pathology | 3 | 14.0 |
Neoplasm Proteins/*metabolism | 4 | 0.0 |
Periodic Acid-Schiff Reaction | 2 | 7.0 |
Interleukin-1/*pharmacology | 3 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Survival Analysis | 8 | 0.0 |
Conjunctiva/*chemistry | 2 | 40.0 |
RNA, Messenger/*analysis | 4 | 0.0 |
Neoplasm Invasiveness/pathology | 2 | 3.0 |
Stomach Neoplasms/*metabolism/pathology | 6 | 10.0 |
Gastric Mucosa/metabolism | 2 | 4.0 |
Chromatography, Ion Exchange | 3 | 0.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Antibodies, Monoclonal | 6 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Carcinoma/*metabolism | 3 | 3.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
*Bile Ducts, Intrahepatic | 2 | 6.0 |
Protein p53/*metabolism | 2 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Receptor, Epidermal Growth Factor/*metabolism | 2 | 0.0 |
Gels | 4 | 4.0 |
Molecular Weight | 5 | 0.0 |
Respiratory System/*metabolism | 3 | 21.0 |
Solubility | 2 | 0.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
Immunoblotting | 3 | 0.0 |
Mucus/*chemistry | 2 | 50.0 |
Bronchoalveolar Lavage Fluid/chemistry | 2 | 3.0 |
Nasal Mucosa/*metabolism | 2 | 10.0 |
Conjunctiva/*physiology | 2 | 100.0 |
Epithelium/physiology | 2 | 2.0 |
Epithelium, Corneal/*physiology | 2 | 50.0 |
Peptides | 2 | 3.0 |
Consensus Sequence | 3 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Mucous Membrane/chemistry | 2 | 16.0 |
Colon/metabolism | 3 | 2.0 |
DNA Mutational Analysis | 2 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Stomach Neoplasms/metabolism/*pathology | 2 | 6.0 |
Polyps/*metabolism/pathology | 2 | 40.0 |
Mucins/*biosynthesis/metabolism | 2 | 40.0 |
Precipitin Tests | 2 | 0.0 |
Mucins/chemistry/*metabolism | 3 | 37.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Hyperplasia/metabolism/pathology | 2 | 14.0 |
Precancerous Conditions/*metabolism/pathology | 2 | 9.0 |
Adenocarcinoma | 2 | 1.0 |
Half-Life | 2 | 0.0 |
Kinetics | 5 | 0.0 |
Gene Expression Regulation, Neoplastic | 9 | 0.0 |
Pancreas/chemistry/pathology | 2 | 25.0 |
Gallbladder Neoplasms/metabolism/*pathology | 2 | 40.0 |
Mucins/*analysis/biosynthesis | 3 | 60.0 |
Hydroxyeicosatetraenoic Acids/*pharmacology | 2 | 20.0 |
Bronchi/*chemistry | 2 | 22.0 |
Bronchitis/metabolism | 2 | 40.0 |
CA-15-3 Antigen/genetics | 3 | 21.0 |
Epithelium/metabolism | 6 | 1.0 |
Chromosomes, Human, Pair 11 | 3 | 0.0 |
Dinoprostone/metabolism | 2 | 2.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Stomach Neoplasms/metabolism/*pathology/surgery | 2 | 28.0 |
Bronchi/cytology/*drug effects/metabolism | 2 | 50.0 |
Tretinoin/*pharmacology | 2 | 0.0 |
DNA Probes | 3 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Bronchi/*cytology | 2 | 13.0 |
Epithelial Cells/cytology | 2 | 2.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Membrane Proteins/genetics | 2 | 0.0 |
*Phenotype | 2 | 0.0 |
*Exons | 2 | 0.0 |
Mucins/chemistry/*genetics | 2 | 20.0 |
DNA/biosynthesis | 2 | 0.0 |
Glycoproteins/metabolism | 2 | 1.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Organ Specificity/genetics | 2 | 1.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Adenocarcinoma, Mucinous/genetics/*metabolism/pathology | 2 | 66.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Adenocarcinoma/classification/*metabolism/pathology | 4 | 80.0 |
Tears/*physiology | 2 | 66.0 |
Chromosomes, Human, Pair 11/*genetics | 3 | 1.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Genomic Library | 3 | 0.0 |
Plasmids | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Gastric Mucosa/chemistry | 2 | 11.0 |
Intestinal Mucosa/chemistry | 2 | 7.0 |
*Multigene Family | 3 | 0.0 |
Protein Conformation | 3 | 0.0 |
Blotting, Southern | 5 | 0.0 |
Epitopes | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Bile Ducts, Intrahepatic/metabolism | 2 | 100.0 |
Liver Neoplasms/secondary | 2 | 3.0 |
DNA, Complementary | 3 | 0.0 |
Repetitive Sequences, Nucleic Acid | 7 | 0.0 |
Introns | 3 | 0.0 |
Child, Preschool | 4 | 0.0 |
Exons | 2 | 0.0 |
Mucous Membrane/metabolism | 2 | 6.0 |
Peptide Mapping | 2 | 0.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Tumor Markers, Biological/analysis | 3 | 0.0 |
Trachea/*metabolism | 2 | 11.0 |
Adenocarcinoma, Mucinous/*metabolism/pathology | 2 | 28.0 |
Glycoproteins/chemistry | 2 | 7.0 |
Infant | 3 | 0.0 |
Treatment Outcome | 2 | 0.0 |
RNA, Neoplasm/metabolism | 2 | 2.0 |
Genome, Human | 2 | 0.0 |
Adenocarcinoma/genetics/metabolism | 2 | 10.0 |
Cluster Analysis | 2 | 1.0 |
Cell Membrane/metabolism | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Esophageal Neoplasms/*metabolism/pathology | 2 | 8.0 |
Epithelium/chemistry | 2 | 1.0 |
Receptor, Epidermal Growth Factor/metabolism | 5 | 0.0 |
Receptor, erbB-2/metabolism | 2 | 1.0 |
Receptor, erbB-3/metabolism | 2 | 6.0 |
Proportional Hazards Models | 2 | 0.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Barrett Esophagus/*metabolism/pathology | 2 | 25.0 |
Enzyme Activation | 2 | 0.0 |
Gene Expression/*genetics | 2 | 1.0 |
Trans-Activators/metabolism | 2 | 0.0 |
